(Q44865180)

6 December 2017

title

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma (English)

1 reference

6 December 2017

0 references

6

Torunn I Yock

1 reference

6 December 2017

Albert Y Lin

1

1 reference

6 December 2017

Nathalie Brophy

2

1 reference

6 December 2017

George A Fisher

3

1 reference

6 December 2017

Sam So

4

1 reference

6 December 2017

Christopher Biggs

5

1 reference

6 December 2017

Lee Levitt

7

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

6 December 2017

1 reference

6 December 2017

volume

103

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

119-125

1 reference

Global cancer statistics in the year 2000.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Risk factors for the rising rates of primary liver cancer in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Therapy of unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20732

7 January 2021

Identifiers

DOI

10.1002/CNCR.20732

1 reference

6 December 2017

1 reference